The Therapeutic Goods Administration (TGA) has issued an alert on Ozempic.
Novo Nordisk has informed the Therapeutic Goods Administration (TGA) that Ozempic (semaglutide) will not be available in Australia from mid-November 2022 until the end of March 2023.
Consumer advice: Patients who are prescribed Ozempic should contact their doctor immediately to have their treatment reassessed. This is especially important around the holiday season and medical services will be limited for several weeks.
For more information and the latest updates, see TGA's alert on About the Ozempic (semaglutide) shortage 2022 and 2023.
The medicines below all contain the following active ingredient: semaglutide
You can select a medicine from this list to find out more — including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS).